HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Christoph Schliemann Selected Research

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)

10/2020Blinatumomab or Inotuzumab Ozogamicin as Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis.
7/2017Successful second allogeneic stem cell transplantation in a patient with T-lymphoblastic leukemia (T-ALL) relapsed as myeloid sarcoma.
9/2013Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Christoph Schliemann Research Topics

Disease

48Neoplasms (Cancer)
04/2024 - 12/2007
41Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
04/2024 - 09/2006
13Infarction (Infarctions)
06/2021 - 03/2008
7Leukemia
04/2024 - 09/2013
6Lymphoma (Lymphomas)
07/2021 - 03/2009
4Hematologic Neoplasms (Hematological Malignancy)
03/2024 - 06/2008
4Thrombosis (Thrombus)
11/2021 - 03/2008
4B-Cell Lymphoma (Lymphoma, B Cell)
11/2021 - 03/2009
4Sarcoma (Soft Tissue Sarcoma)
01/2021 - 01/2018
4Neoplasm Metastasis (Metastasis)
10/2018 - 07/2009
3Lung Neoplasms (Lung Cancer)
01/2021 - 01/2015
3Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
10/2020 - 09/2013
3Squamous Cell Carcinoma (Epidermoid Carcinoma)
01/2017 - 01/2015
3Adenocarcinoma
01/2017 - 03/2008
3Fibrosarcoma
12/2016 - 12/2010
2Hemorrhage
10/2023 - 01/2014
2Infections
11/2022 - 10/2016
2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL)
01/2022 - 07/2017
2Disease Progression
01/2022 - 10/2020
2Hodgkin Disease (Hodgkin's Disease)
11/2021 - 01/2021
2Non-Hodgkin Lymphoma (Lymphosarcoma)
01/2021 - 03/2009
2Papilloma (Papillomatosis)
01/2021 - 11/2014
2Multiple Myeloma
01/2021 - 08/2020
2Recurrent respiratory papillomatosis
01/2021 - 11/2014
2Acute Promyelocytic Leukemia
01/2021 - 02/2018
2Cytokine Release Syndrome
10/2020 - 05/2015
2Small Cell Lung Carcinoma (Small Cell Lung Cancer)
05/2019 - 11/2017
2Lymphadenitis (Adenitis)
01/2019 - 12/2009
2Salivary Gland Neoplasms (Salivary Gland Cancer)
10/2018 - 08/2018
2Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2018 - 01/2017
2Myeloid Sarcoma (Chloroma)
07/2017 - 09/2013
2Melanoma (Melanoma, Malignant)
12/2016 - 10/2012
1Pathologic Complete Response
04/2024
1Hematologic Diseases (Blood Diseases)
01/2024
1Cardiovascular Diseases (Cardiovascular Disease)
10/2023
1Hypoxia (Hypoxemia)
10/2023
1Cardiomyopathies (Cardiomyopathy)
04/2023
1Heart Diseases (Heart Disease)
04/2023
1Coronary Disease (Coronary Heart Disease)
04/2023
1Myelodysplastic Syndromes (Myelodysplastic Syndrome)
01/2023

Drug/Important Bio-Agent (IBA)

17Proteins (Proteins, Gene)FDA Link
10/2023 - 03/2008
15Thromboplastin (Tissue Factor)IBA
10/2023 - 12/2010
9Cytarabine (Cytosar-U)FDA LinkGeneric
04/2024 - 09/2013
9Peptides (Polypeptides)IBA
03/2022 - 07/2009
8AntibodiesIBA
11/2022 - 12/2009
8CD13 Antigens (Alanine Aminopeptidase)IBA
06/2021 - 01/2014
6Monoclonal AntibodiesIBA
12/2022 - 06/2008
6AntigensIBA
07/2022 - 06/2008
6LigandsIBA
03/2022 - 09/2006
6Biomarkers (Surrogate Marker)IBA
11/2021 - 01/2014
5Membrane Proteins (Integral Membrane Proteins)IBA
10/2015 - 07/2009
5Fibronectins (Fibronectin)IBA
07/2015 - 06/2008
4CytokinesIBA
01/2022 - 01/2010
4Interleukin-2 (IL2)IBA
07/2015 - 12/2010
3DecitabineFDA Link
12/2022 - 01/2019
3Therapeutic UsesIBA
11/2020 - 01/2014
3Rituximab (Mabthera)FDA Link
07/2015 - 03/2009
3Coloring Agents (Dyes)IBA
09/2013 - 12/2009
3F8 monoclonal antibodyIBA
09/2013 - 06/2008
2Chimeric Antigen ReceptorsIBA
10/2023 - 01/2021
2AnthracyclinesIBA
04/2023 - 02/2018
2Transcription Factors (Transcription Factor)IBA
01/2023 - 06/2022
2nintedanibIBA
01/2023 - 01/2016
2BI 836858IBA
12/2022 - 01/2022
2Messenger RNA (mRNA)IBA
11/2022 - 01/2017
2Azacitidine (5 Azacytidine)FDA Link
12/2021 - 01/2019
2GTP-Binding Proteins (G-Protein)IBA
11/2021 - 12/2019
2Calcitonin Receptors (Calcitonin Receptor)IBA
11/2021 - 12/2019
2Neuropeptide Receptors (Neuropeptide Receptor)IBA
11/2021 - 12/2019
2Bevacizumab (Avastin)FDA Link
01/2021 - 11/2014
2Immunoglobulin FragmentsIBA
01/2021 - 06/2008
2Tretinoin (Retinoic Acid)FDA LinkGeneric
01/2021 - 02/2018
2Doxorubicin (Adriamycin)FDA LinkGeneric
01/2021 - 12/2016
2PhosphatidylserinesIBA
01/2020 - 12/2016
2ZincIBA
11/2017 - 01/2017
2Peptide Hydrolases (Proteases)FDA Link
11/2017 - 01/2017
2OsteopontinIBA
10/2012 - 05/2012
2ProteomeIBA
04/2011 - 07/2009
2Protein Isoforms (Isoforms)IBA
02/2010 - 12/2009
2TenascinIBA
02/2010 - 12/2009
1venetoclaxIBA
04/2024
1Mitoxantrone (Novantrone)FDA LinkGeneric
04/2024
1Cetrimonium (CTAB)IBA
03/2024
1Histone DemethylasesIBA
03/2024
1glasdegibIBA
02/2024
1Gemtuzumab (Mylotarg)FDA Link
02/2024
1omega-Chloroacetophenone (Mace)IBA
10/2023
1tyramine-deoxysorbitolIBA
01/2023

Therapy/Procedure

44Therapeutics
04/2024 - 12/2007
17Drug Therapy (Chemotherapy)
04/2024 - 12/2010
7Stem Cell Transplantation
11/2021 - 08/2013
5Hematopoietic Stem Cell Transplantation
09/2023 - 05/2015
3Cell Transplantation
01/2023 - 01/2022
3Radiotherapy
01/2020 - 01/2018
2Secondary Prevention
01/2024 - 11/2023
2Molecular Targeted Therapy
06/2022 - 05/2019
2Salvage Therapy
11/2021 - 10/2020
1Remission Induction
04/2024
1Percutaneous Coronary Intervention
10/2023
1Induction Chemotherapy
04/2023